Potential prognostic value of PD-L1 and NKG2A expression in Indonesian patients with skin nodular melanoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-0500
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Potential prognostic value of PD-L1 and NKG2A expression in Indonesian patients with skin nodular melanoma ; volume:14 ; number:1 ; day:28 ; month:5 ; year:2021 ; pages:1-6 ; date:12.2021
BMC Research Notes / Biomed Central; 14, Heft 1 (28.5.2021), 1-6, 12.2021
- Urheber
-
Saputro, Ridwan Dwi
Rinonce, Hanggoro Tri
Iramawasita, Yayuk
Ridho, Muhammad Rasyid
Pudjohartono, Maria Fransiska
Anwar, Sumadi Lukman
Setiaji, Kunto
Aryandono, Teguh
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13104-021-05623-7
- URN
-
urn:nbn:de:101:1-2021092419383405487699
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
03.09.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Saputro, Ridwan Dwi
- Rinonce, Hanggoro Tri
- Iramawasita, Yayuk
- Ridho, Muhammad Rasyid
- Pudjohartono, Maria Fransiska
- Anwar, Sumadi Lukman
- Setiaji, Kunto
- Aryandono, Teguh
- SpringerLink (Online service)
Ähnliche Objekte (12)
MIIP downregulates PD-L1 expression through HDAC6 in cutaneous melanoma
Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells
IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression
The Regulation of PD-L1 Secretion in Extracellular Vesicles by Melanoma Cells
RSK1 activation promotes invasion in nodular melanoma
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma
MIIP downregulates PD-L1 expression through HDAC6 in cutaneous melanoma
Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells
IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression
The Regulation of PD-L1 Secretion in Extracellular Vesicles by Melanoma Cells
RSK1 activation promotes invasion in nodular melanoma
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma
MIIP downregulates PD-L1 expression through HDAC6 in cutaneous melanoma
Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells
IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression
The Regulation of PD-L1 Secretion in Extracellular Vesicles by Melanoma Cells
RSK1 activation promotes invasion in nodular melanoma
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma